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Introduction: Colorectal cancer (CRC) is the third most common and second
most deadly malignancy in the world with an estimated 1. 9 million cases and
0.9 million deaths in 2020. The 5-year overall survival for stage I disease is 92%
compared to a dismal 11% in stage IV disease. At initial presentation, up to 35%
of patients have metastatic colorectal cancer (mCRC), and 20–50% of stage II
and III patients eventually progress to mCRC. These statistics imply both that
there is a proportion of early stage patients who are not receiving adequate
treatment and that we are not adequately treating mCRC patients.
Body: Targeted therapies directed at CRC biomarkers are now commonly
used in select mCRC patients. In addition to acting as direct targets, these
biomarkers also could help stratify which patients receive adjuvant therapies
and what types. This review discusses the role of RAS, microsatellite instability,
HER2, consensus molecular subtypes and ctDNA/CTC in targeted therapy and
adjuvant chemotherapy.
Discussion: Given the relatively high recurrence rate in early stage CRC
patients as well as the continued poor survival in mCRC patients, additional
work needs to be done beyond surgical management to limit recurrence and
improve survival. Biomarkers offer both a potential target and a predictive
method of stratifying patients to determine those who could beneﬁt from
adjuvant treatment.
KEYWORDS

adjuvant chemotherapy, targeted therapies, colorectal cancer, individualized
medicine, biomarkers

Introduction
Colorectal cancer (CRC) is the third most common and second most deadly
malignancy in the world with an estimated 1.9 million cases and 0.9 million deaths in
2020 (1). With improved screening and enhanced surgical options, the overall survival
in patients with CRC has improved over time with a current overall relative survival of
65% at 5 years (2). However, this survival varies greatly as the disease progresses. The
5-year overall survival for stage I disease is 92% compared to a dismal 11% in stage IV
disease (3). At initial presentation up to 35% of patients have metastatic colorectal cancer
(mCRC) with 20–50% of stage II and III patients eventually progressing to mCRC (4).
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system is unable to function leading to an accumulation of
errors in the DNA (10). This inactivation stems from either
germline mutations in the MMR genes themselves or somatic
hypermethylation of CpG islands surrounding the promotor
region in the genes. Germline mutations in MMR lead to
hereditary non-polyposis colorectal cancer (HNPCC or Lynch
Syndrome) which causes ∼3% of all CRCs (11). The somatic
hypermethylation of CpG islands is known as the CpG island
methylator phenotype (CIMP). These CIMP tumors comprise
the majority of sporadic MSI-H CRCs (12). These CIMP
tumors are in contrast to tumors with chromosomal instability
(CIN) which follow the more traditional pathway of initial
APC mutation causing a tubular adenoma with subsequent
accumulated mutations leading to cancer (13).
MSI-H/dMMR is more common among stage II tumors
compared with stage III CRCs and relatively uncommon in stage
IV (metastatic) CRCs suggesting MSI-H/dMMR tumors are less
likely to metastasize. Indeed, MSI-H/dMMR is independently
associated with improved survival compared with tumors with
proficient MMR (pMMR) (14). In addition, MSI-H/dMMR
tumors also have lower recurrence rates compared with pMMR
tumors (15). It has also been shown that MSI-H/dMMR tumors
do not respond well to 5-FU-based adjuvant chemotherapy
(16). Indeed, cells require a competent MMR system for 5FU to be effective (17). Current recommendations suggest that
patients with stage II colon cancer with MSI-H/dMMR should
not receive adjuvant 5-FU-based chemotherapy based on this
known favorable prognosis and lack of response to therapy.
Unlike 5-FU, oxaliplatin leads to DNA-cross linking and
inhibits DNA synthesis and transcription. This damage is not
recognized by the MMR system and dMMR tumors should
not be resistant to oxaliplatin. The MOSAIC trial revealed
improvement in 5-year DFS and 6-year OS for stage III colon
cancers with the addition of oxaliplatin to 5-FU regardless of
MMR status (18). Ten year follow up of the MOSAIC trial
confirmed the benefit of oxaliplatin as adjuvant therapy in stage
II/III colon cancers. More recent work has revealed a potential
benefit to the addition of oxaliplatin to fluoropyrimidines in
adjuvant chemotherapy for MSI-H stage III colon cancer (19).
In addition to standard chemotherapy, additional treatment
options exist that may specifically benefit in MSI-H/dMMR
patients. As previously discussed, MSI-H/dMMR have a baseline
improved clinical course compared to tumors with pMMR. This
may be due to their hypermutable phenotype contributing to
the production of abnormal peptides that serve as neoantigens,
producing specific antitumor immune responses leading to
decreased tumor growth and metastasis (20). Sporadic MSIH CRC have a distinct phenotype that includes right colon
predominance, increased prevalence in women and poor
differentiation/mucinous histology. MSI-H tumors also exhibit
an elevated number of tumor-infiltrating lymphocytes (TILs),
supporting this neoantigen hypothesis (21). This baseline local
immune control contributes to improved patient survival in

Current recommendations suggest that patients with stage III
(lymph node-positive) colon cancer undergo surgical resection
followed by adjuvant chemotherapy. There continues to be
controversy about the survival benefit of chemotherapy in
patients with stage II disease (5). The intention of adjuvant
chemotherapy is to decrease the chances of recurrence in the
setting of curative resection. As stage II disease is node-negative,
there is a presumption of local disease without metastases.
Current recommendations suggest that stage II patients do
not receive adjuvant therapy, however up to 23% will have
a recurrence within 5 years indicating we are not currently
capturing a population who may indeed have initial early spread
and would benefit from additional therapy (6). Therefore, some
argue that “high risk” stage II patients should receive adjuvant
therapy in hopes of rescuing this population who will eventual
relapse. Some high risk factors in stage II disease that have been
suggested as warranting adjuvant treatment include T4 tumors,
<12 lymph nodes harvested at surgery, presence of bowel
obstruction or perforation, poorly differentiated tumors, and the
presence of lymphovascular/perineural invasion (7). Of these,
only T4 disease has been validated to help identify the subset of
stage II patients who benefit from adjuvant chemotherapy (8).
Standard adjuvant treatment regimens for high risk stage II
or stage III disease include combination therapies of CAPEOX
(capecitabine and oxaliplatin) and FOLFOX (leucovorin,
fluorouracil (5-FU), and oxaliplatin). However, only 20% of
patients benefit from adjuvant chemotherapy, exposing 80%
of patients to unnecessary toxicity (9). In addition to these
combination therapies of classic chemotherapy agents, newer
targeted agents exist and may confer benefits in specific
patient populations. Better biomarkers that stratify patient
risk (prognostic) and predict therapeutic responses (predictive)
could reduce the exposure of patient populations to unnecessary
toxicity and increase the likelihood of eliminating the chance
of recurrence in patients after resection. Biomarkers could aid
in defining the optimum regimen of adjuvant chemotherapy,
the duration of treatment, the utility of additional targeted
treatments, and which patient populations should receive it
(Table 1).

Microsatellite instability
High microsatellite instability (MSI-H) is the phenotype of
a deficient mismatch repair (dMMR) system and is present in
about 15% of colorectal cancers. Microsatellites are short tandem
repeats of single nucleotide or di-, tri-, or tetra-nucleotides
in DNA sequences found throughout the tumor genome and
are a marker of a hypermutable phenotype. The mismatch
repair (MMR) system functions to rectify errors that may occur
during DNA replication. With the inactivation of at least one
of the DNA MMR genes (MLH1, MSH2, MSH6, and PMS2)
through either mutations or transcriptional silencing, the MMR
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TABLE 1 Emerging and established biomarkers.

Biomarker
Microsatellite instability

Targeted drugs

Resistance

Chemotherapy

Pembrolizumab Nivolumab (PD-1

Stage II dMMR patients have not been

inhibitors) Ipilimumab (CTLA4

shown to benefit from 5-FU

inhibitor)

adjuvant therapy Oxaliplatin may have a
benefit in MMR tumors

RAS

Small molecules targeting G12C variant

BRAF

BRAF inhibitors

Confers anti-EGFR agent
resistance
Negative predictor of response to
anti-EGFR therapies

HER2

APC

Trastuzumab Lapatinib Pertuzumab

Predict resistance to anti-EGFR

HER2 high patients may benefit from

Trastuzumab deruxtecan

therapies

adjuvant chemotherapy

Tankyrase inhibitors

CEA

CEA high patients may benefit from
adjuvant chemotherapy

NTRK

Enterctinib Larotrectinib

Biomarkers offer targets for directed drug therapy as well as potential markers of resistance. In addition, biomarkers can be used to help guide chemotherapy decisions.

chemotherapy and the addition of an immune checkpoint
inhibitor could better optimize the alignment of treatment
groups and therapies.

MSI-H CRC and also sensitizes tumors in these patients to
immune checkpoint inhibitors targeting either programmed cell
death-1 protein (PD-1) or cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4). PD-1 is expressed on T cells, and binding
of its ligands (PD-L1 and PD-L2) downregulates T cell effector
function. In that context, tumors can escape immune detection
by upregulating expression of programmed death ligand 1 (PDL1) (22). Inhibitors of PD-1 block the receptor from interacting
with its ligands, promoting tumor cell killing by effector T cells.
Inhibitors of PD-1, pembrolizumab (Keytruda) and nivolumab
(Opdivo), are FDA-approved for patients with mCRC with
dMMR or MSI-H and confer a significant survival benefit
when used (23, 24). An additional target, CTL-4, is transiently
expressed on activated T cells with its expression inhibiting
the production of cytokines and providing a negative feedback
signal to T cells prompting T cell cycle arrest. Inhibition of
CTLA-4 may lead to reactivation of T cells allowing them to
overcome tumor-induced immune tolerance (25). Ipilimumab
(Yervoy) is an anti-CTLA-4 antibody used in metastatic
dMMR/MSI-H patients in combination with nivolumab (26).
This combination of nivolumab and low-dose ipilimumab
produced an objective response rate of 64%, complete response
rate of 9%, and disease control rate of 84%, all of which were
durable (27). While the results of immune checkpoint blockade
in dMMR/MSI-H CRC patients have been encouraging, single
agent checkpoint inhibitors are not efficacious in patients with
pMMR which makes up the majority of CRC patients (28). In
addition, while immune checkpoint inhibitors are approved in
mCRC dMMR/MSI-H disease, their utility as adjuvant therapy
in localized disease and their efficacy in combination are being
explored (29, 30). The use of dMMR/MSI-H as a biomarker in
determining the need for adjuvant therapy, the type of adjuvant

Frontiers in Medicine

MAPK pathway (Ras-Raf-MEK-ERK)
Gain or loss of function mutations in proteins in the
mitogen-activated protein kinase (MAPK) pathway lead to
dysregulated proliferative cell signaling ultimately driving
tumorigenesis. The first protein to be activated in the pathway
is RAS, a commonly mutated protein in CRC (31). In the
normal cell, activation of RAS begins with an extracellular ligand
binding to a receptor-linked tyrosine kinase like epidermal
growth factor receptor (EGFR). This binding activates the
tyrosine kinase in the cytoplasmic domain of the receptor
causing phosphorylation of EGFR and interaction with RAS.
This triggers RAS, a GTPase, to exchange a GDP molecule for
GTP, activating the pathway and initiating a kinase cascade
leading to the activation of Raf, MAPK/ERK (MEK1 or 2) and
ultimately MAPK (32).
RAS (KRAS, NRAS, and HRAS) is the most frequently
mutated gene family in cancers with the most common
oncogenic mutant of the RAS family being KRAS G12C.
KRAS mutations are present in 30–50% of CRC with NRAS
mutated in 3–5% and HRAS mutated in <1% (33, 34). KRAS
mutations account for up 45% of mCRC and ∼15–37% of
early stage tumors (35, 36). Historically, RAS was considered
“undruggable” due to its picomolar affinity for GTP/GDP, the
absence of identified allosteric regulatory sites, and the necessity
of wild type RAS in normal biologic functions. However, small
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previously-treated patients with BRAF V600E mCRC improved
overall survival and progression-free survival compared to
standard chemotherapy (52). Moreover, triple therapy inhibiting
BRAF, EGFR, and MEK is effective against BRAFV600 tumors
(53, 54).

molecules that specifically inhibit the G12C variant have been
identified, making RAS a potential therapeutic target (37).
Monoclonal antibodies targeting EGFR, including
cetuximab and panitumumab, are routinely used in mCRC.
These monoclonal antibodies compete with the endogenous
EGFR ligand and after binding, block phosphorylation,
leading to internalization and degradation of the receptor.
Cetuximab has been approved as a first-line treatment in
mCRC patients with wild-type KRAS in combination with
chemotherapy (38). Unfortunately, the addition of cetuximab
to FOLFOX failed to improve disease-free or overall survival
in post-resection stage III colon cancer patients (39). There is
emerging evidence of the effectiveness of combining EGFR and
KRAS G12C inhibitors in advanced disease. EGFR signaling
has been identified as the primary mechanism of resistance to
KRAS G12C inhibitors and this combination may overcome this
resistance (40). The combination of anti-EGFR and KRAS G12C
inhibitors is effective in cell lines, patient-derived organoids,
and xenografts (41).
One downstream effector target of RAS is the RAF family,
made up of c-RAF1, BRAF, and ARAF. Of these, BRAF is
the most frequently mutated in tumors (42). Outside the
constitutive activation of RAS, mutations in codon 600 of the
BRAF gene produce RAS-independent activation of the MAPK
pathway, leading to increased cell proliferation and survival.
Sporadic MSI CRCs often show increased co-occurrence of
BRAFV600E mutations compared to CRCs overall (43). These
somatic BRAFV600E mutations increase BRAF/MEK/ERK
signaling leading to the CIMP which silences MLH1, ultimately
resulting in dMMR. The presence of a BRAF mutation indicates
a sporadic MSI tumor and virtually excludes the diagnosis of
Lynch syndrome (44). Patients with BRAF mutations experience
poorer survival compared to patients with wild-type BRAF
(45). BRAF mutations are associated with more right-sided
primary tumors and with an increased risk of metastasis to the
peritoneum and distant lymph nodes (46). BRAF and KRAS
mutations are not coincident in tumors, and many KRAS wild
type mCRC have BRAF mutations. These mutations identify
tumors that are unresponsive to anti-EGFR therapies when
combined with chemotherapy (47).
BRAF inhibitors are used extensively in BRAFV600E
melanomas with positive treatment results (48). While BRAF
inhibitor monotherapy in BRAFV600 melanoma leads to
response rates of >50%, only ∼5% of BRAFV600 CRC
patients respond (49). Since EGFR mediates resistance to BRAF
inhibitors, the differing expression of EGFR in CRC, compared
to melanoma, may explain this difference in response rates. In
CRC, BRAF inhibition leads to feedback activation of EGFR
which increases proliferation even in the presence of BRAFV600
inhibition (50). In contrast, simultaneous blockade of EGFR
and BRAF produced synergistic inhibition of tumor growth
in murine CRC models through enhanced MAPK suppression
(51). Dual treatment with EGFR and BRAF inhibitors in
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HER2
HER2 (human epidermal growth factor receptor 2) is a
transmembrane receptor that acts as an intracellular tyrosine
kinase. Homo- or heterodimerization of HER2 with an
additional member of the EGFR family (EGFR/HER2/ERBB)
leads to the activation of either the RAS-RAF-ERK or PI3KPTEN-AKT pathway leading to increased cellular proliferation.
The amplification of the HER2 gene or overexpression of the
HER2 protein has been targeted in solid tumor malignancies
other than CRC. While therapies that block HER2 (trastuzumab,
lapatinib, and pertuzumab) have gained prominence in treating
patients with HER2-overexpressing tumors in these other
malignancies, there are no HER-2-directed therapies approved
by the FDA to treat CRC.
Preclinical work initially showed that HER2-amplified
tumors were responsive to dual HER2-directed therapies, but
not individual agents alone. Using this information, a phase
2 trial examining dual HER2 therapy comprising a tyrosine
kinase inhibitor and anti-HER2 monoclonal antibody in KRAS
wild-type, HER2-positive mCRC patients demonstrated that
30% of patients had objective responses and 44% had stable
disease (55). A phase 2 trial of trastuzumab deruxtecan, a
HER2-targeted antibody-drug conjugate, in patients who had
previously progressed on at least two previous treatment
regimens, showed an objective response rate of 45.3% (56).
In quadruple WT populations (KRAS, NRAS, BRAF, and
PIK3CA WT) treated with anti-EGFR therapies, the HER2
pathway may function as a bypass leading to resistance to antiEGFR agents (57) (Figure 1). Indeed, HER2 expression predicts
unresponsiveness to EGFR-targeted therapies in mCRC (58).
In addition to predicting response to HER2 and EGFR
directed therapies, HER2 expression could help identify which
patients may have a benefit from adjuvant chemotherapy.
One study showed that among HER2 high patients, those
who received chemotherapy had better OS and DFS than
chemotherapy naïve patients. They showed no difference in
outcomes among chemo-treated and chemo-naïve patients in
the HER2 low group (59). This implies HER2 expression in CRC
can be used as a direct target as well as a biomarker of resistance,
and even eventually a guide in chemotherapy.

APC
In most CRCs Wnt/β-catenin signaling is activated by
loss-of-function mutations in the adenomatous polyposis coli
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FIGURE 1

Epidermal growth factor signaling pathways. Multiple potential targets for therapy exist along epidermal growth factor receptor (EFGR) and
human epidermal growth factor receptor 2 (HER2) pathways. In addition, ampliﬁcation of HER2 has been implicated in anti-EGFR therapy
resistance as activation of the HER2 pathway may bypass blockade of EGFR. Created with BioRender.com. Adapted from Crutcher et al. (37)
Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal
cancer patients, Expert Review of Clinical Pharmacology.

(APC) gene. The β-catenin-dependent Wnt signaling pathway
is initiated by the binding of secreted cysteine-rich Wnt
glycoproteins to LRP5/6 receptors and FZD receptors. The
secretion of Wnt ligands depends on acylation by Porcupine
(PORCN) (60). Binding of the Wnt ligands to LRP5/6 and
FZD receptors on the cell surface induces disheveled (DVL)
which leads to suppression of glycogen synthase kinase 3β
(GSK3β). Together GSK3β, axin, and casein kinase 1 (CK1a)
form a destruction complex which is stabilized by APC
and phosphorylates β-catenin, priming it for degradation
by the ubiquitin-proteosome pathway. In the presence of
Wnt, and suppression of GSK3β, un-phosphorylated β-catenin
accumulates in the cytosol, translocates to the nucleus,
and interacts with TCF/LEF transcription factors to trigger
expression of Wnt targets like c-Myc, cyclin D1, and CDKN1A
(61). Inactivating mutations of APC de-stabilize the destruction
complex, leading to activation of the Wnt signaling pathway
which drives tumorigenesis.
While dysregulation of the Wnt/β-catenin signaling pathway
is common in CRCs, this pathway lacks druggable molecular
targets. Tankyrases (TNKSs) are members of poly-ADP-ribose
polymerases (PARPs) family that poly-ADP-ribosylate and
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downregulate axins resulting in an overexpression of β-catenin.
Tankyrase inhibitors (TNKSi) have been developed as potential
therapeutic agents in CRC (62). APC may effect response to
tankyrase inhibitors. It has been shown that drug-sensitive CRC
cells had truncated forms of APC that lacked all seven β-cateninbinding 20-amino acid repeats (AARs) resulting in cell response
to TNKSi. Conversely, drug-resistant CRC cells had longer
forms of APCs with two of more 20AARs (63). Identification
of APC status could be prognostic in determining potential
response to TNKSi.

CEA
Carcinoembryonic antigen (CEA) is a cell adhesion
molecule that is elevated in the serum of patients with a
variety of cancers, including CRC. CEA levels have been used
postoperatively in surveillance and higher preoperative CEA
levels have been shown to be an independent predictor of
both overall and disease-free survival rates. In addition, patients
with node-negative colon cancer but elevated preoperative CEA
levels have a poor prognosis similar to those with node-positive
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microenvironment is pro-inflammatory (70). Indeed, TGFβ may
be immunosuppressive and drive immune evasion in CRC
(71). Alternatively, CMS2 and CMS3 tumors are “cold” tumors
reflecting low immune cell infiltrates. CMS2 and CMS3 tumors
may respond to alternative immunogenic stimuli, like vaccines
or co-stimulatory compounds, but do not respond to immune
checkpoint inhibitors. CMS2 and CMS3 tumors also respond to
anti-VEGF agents (72). CMS classification has the potential to
provide prognostic information, since CMS2 and CMS3 tumors
have a better prognosis than CMS1 and CMS4. One study
examining CMS status among stage II CRC found adjuvant
chemotherapy had no benefit in CMS1 subtype tumors, and a
significant decrease in DFS for CMS4 tumors (73). In contrast,
stage II and III patients with either the CMS2 or CMS3 have
benefit from adjuvant therapy (74). While not currently used
in clinical practice CMS subtypes may eventually help guide
targeted and chemotherapy decisions.

disease (64). These patients may be candidates for adjuvant
chemotherapy. As previously discussed stage II colon cancers
do not typically receive adjuvant chemotherapy. However those
stage II patients with high risk features may benefit from
adjuvant therapy but there has been difficulty in defining this
group. Studies have shown that CEA levels could potentially
be used to risk stratify stage II patients and inform treatment
decisions (65).

NTRK
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions
are extremely rare in CRC occurring in less than 1% of tumors
(66). However, they are more frequently found in patients
with dMMR (67). The FDA has approved two tropomyisin
receptor kinase (TRK) inhibitors, entrectinib, and larotrectinib,
for use in patients with NTRK fusion-bearing cancers in either
a worsening metastatic setting or locally advanced unresectable
tumors (68). This is an example of tissue agnostic treatments that
can be used in any solid tumor, not just CRC.

Circulating tumor cells (CTCs) and
circulating tumor DNA (ctDNA)

Consensus molecular subtypes

The concept of a “liquid biopsy” for solid tumors has recently
emerged, reflecting sampling convenience and its ability to
capture the varying molecular markers of a solid tumor. Liquid
biopsies have multiple advantages over tissue biopsies, such as
assessing molecularly divergent metastatic lesions, capturing the
heterogeneity of a tumor, and evaluating potential resistance
mutations in real time as treatment progresses. Circulating
tumor cells (CTCs) are individual, or clusters of, cancer cells
circulating in the bloodstream resulting from passive shedding
or intravasation from the primary lesion or metastases (75). The
amount of detectable CTCs detected is associated with treatment
outcomes and overall survival (76). In contrast to CTCs, cellfree circulating tumor DNA (ctDNA) comprises somatic and
epigenetic DNA alterations from tumor cells released into
bloodstream following apoptosis or necrosis. ctDNA is more
abundant within the bloodstream than CTCs but both can be
detected and interrogated for actionable treatment targets and
emergent resistant sub-clones, therefore assisting in treatment
decisions before and after initiation of therapy.
There is an established relationship between ctDNA and
tumor burden, with ctDNA positivity increasing with CRC
stage (77). In this sense, ctDNA could identify high risk
early stage patients. In addition, as discussed earlier, there are
several biomarkers that can predict prognosis or treatment
response in CRC such as MSI-H/dMMR (susceptibility to
immune checkpoint inhibitors) as well as KRAS/BRAF (antiEGFR resistance). A study interrogating the emergence of
mutated KRAS alleles in ctDNA during anti-EGFR therapy
revealed that these alleles decline when treatment is suspended,
demonstrating that liquid biopsies can be used to track
treatment resistance (78). The ability to accurately capture these

An additional method of categorizing CRCs that may help
guide treatment decisions are the Consensus Molecule Subtypes
(CMS). CMS1 or MSI immune tumors account for 14% of
CRCs. They have a high rate of mutations, with frequent BRAF
mutations, and sizeable immune infiltration. The majority of
MSI tumors fall in this category and, as previously discussed,
these tumors are responsive to immune checkpoint inhibitors.
In addition, the BRAFV600E mutation predisposes resistance to
treatment with anti-EGFR agents. CMS2 or canonical tumors
make up 37% of tumors and have upregulated Wnt/Myc
signaling. These tumors stem from the canonical adenomato-carcinoma sequence typified by the initial loss of APC, a
following activating mutation in KRAS, and an ultimate loss
of TP53. CMS3 or metabolic tumors comprise 13% of cases
and have frequent KRAS mutations and dysregulation of cancer
metabolic pathways. As discussed previously, KRAS mutation
may indicate a poor response to anti-EGFR therapy. CMS4 or
mesenchymal tumors form 23% of cases and are characterized
by transforming growth factor beta (TGFβ) pathway activation,
enhanced angiogenesis, stromal activation and inflammatory
infiltrates (69).
These four molecular subtypes can be broadly divided into
“hot” and “cold” CRCs based on immune infiltration. The
high immune infiltration of CMS1/MSI-H tumors has been
discussed, as well as their responsiveness to treatment with
immune checkpoint inhibitors. While CMS4 tumors also have
increased immune cell infiltrates, responses to immunotherapy
may be altered by TGFβ signaling. In comparison to the antitumor immune environment of CMS1 tumors, the CMS4 tumor
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markers prior to the initiation treatment could help tailor
therapeutic planning. Furthermore, the ability to track these
markers during treatment could both ensure treatment response
and monitor for developing resistance.
Currently, there is controversy as to what proportion
of stage II CRC patients should receive adjuvant therapy.
While some high risk characteristics have been suggested,
these are not validated and there is no consensus (79). In
stage II CRC, post-operative patients who were positive for
ctDNA were at extremely high risk for recurrence when not
treated with adjuvant chemotherapy (80, 81). A study surveying
ctDNA status in patients after curative-intent surgery revealed
that 100% of patients with ctDNA detected after treatment
completion ultimately recurred (82). In patients with resectable
colorectal liver metastases, patients with ctDNA detected after
surgery had a significantly poorer relapse-free survival and
overall survival. In addition, all patients with persistently
detectable ctDNA after adjuvant chemotherapy recurred (83). A
study in stage I-III patients revealed that in the majority, ctDNA
identified relapse after definitive treatment. The same study also
showed that ctDNA status was independently associated with
relapse after adjusting for other clinicopathologic risk factors
(84). ctDNA could potentially be used as an adjunct to the
traditional TNM staging and other potential prognostic markers
in determining which patients receive adjuvant therapy.

Increasing levels of ctDNA have been shown to be correlated
with worse survival showing ctDNA could potentially be
included in staging algorithms (85). In addition to sampling at
diagnosis in order to stage and determine molecular markers,
ctDNA levels and mutation expression can be followed to
monitor for recurrence or emerging treatment resistance. While
CMS subtypes currently are not recommended for use in clinical
practice, this may change as a greater understanding of their
biology emerges.
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Summary
Despite improvements in screening and surgical
interventions, CRC has remained the second most common
cause of cancer-related death in the United States. While it
has an overall favorable relative survival 5 year survival of
65%, inadequacies in treatments are revealed when stage by
stage prognosis is examined (2). The 5-year overall survival for
stage I disease (small, no lymph node spread) is 92% compared
to 11% in stage IV (metastatic) (3). Approximately 35% of
patients have metastatic disease at initial presentation with
20–50% of stage II and stage III patients eventually progressing
to metastatic disease (4). These survival statistics illuminate
multiple areas for improvement in the treatment of CRC. The
high recurrence rates among patients who present with localized
disease indicates missed opportunities for curative treatment
in some patient populations. Currently, adjuvant therapy is
consistently given to patients with stage III disease (positive
lymph nodes) with some controversy in stage II disease. Again,
the high recurrence rates among this population suggest there
could be additional benefit from adjuvant treatment.
Further, much like innovations in targeted therapy, strides
have been made in novel sampling techniques. ctDNA in
the blood of CRC patients reflects the entire tumor genome.
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